We are live on ! Find out more
LLY icon

Eli Lilly

Positive
Neutral
Negative
Sentiment 3-Months
Positive 61.7%
Neutral 25.4%
Negative 12.9%

Negative
Proactive Investors
5 hours ago
Novo Nordisk sues Eli Lilly over GLP-1 drug advertising claims
Novo Nordisk (NYSE:NVO) has filed a federal lawsuit against Eli Lilly, alleging that its rival's advertising campaigns for blockbuster GLP-1 obesity and diabetes drugs mislead consumers about the effectiveness of competing treatments. The complaint, filed on July 21, 2026, in the US District Court for the District of New Jersey, challenges nationwide advertisements for Lilly's Zepbound and Mounjaro that Novo claims rely on outdated clinical trial data and create an inaccurate comparison between the companies' medicines.
Novo Nordisk sues Eli Lilly over GLP-1 drug advertising claims
Positive
Zacks Investment Research
5 hours ago
GLP-1 Titans Clash: Comparing Eli Lilly and Novo Nordisk
LLY's leadership in obesity drugs, expanding pipeline and stronger growth outlook set it apart as investors weigh it against NVO in 2026.
GLP-1 Titans Clash: Comparing Eli Lilly and Novo Nordisk
Negative
Barrons
5 hours ago
Novo Nordisk Sues Eli Lilly Over Weight-Loss Drug Advertising
Novo Nordisk alleges Eli Lilly falsely advertised Zepbound and Mounjaro by claiming the drugs outperform Wegovy and Ozempic.
Novo Nordisk Sues Eli Lilly Over Weight-Loss Drug Advertising
Negative
Bloomberg Markets and Finance
6 hours ago
Novo Sues Rival Lilly Over Weight-Loss Ads
Novo Nordisk A/S is suing rival drugmaker Eli Lilly & Co. for showing what it calls are misleading ads about obesity drugs in the US. Novo says Lilly is using outdated information when comparing Novo's Wegovy to Lilly's Zepbound.
Novo Sues Rival Lilly Over Weight-Loss Ads
Neutral
CNBC Television
6 hours ago
Cramer's Mad Dash: Eli Lilly
CNBC's Jim Cramer delivers his daily Mad Dash.
Cramer's Mad Dash: Eli Lilly
Negative
Schaeffers Research
6 hours ago
Popular Drug Maker Slams GLP-1 Peer on False Advertising
Novo Nordisk (NYSE:NVO) stock is down 1% at $49.14, after the drugmaker filed a lawsuit against rival Eli Lilly (LLY), citing misleading advertising for its GLP-1 drugs.
Popular Drug Maker Slams GLP-1 Peer on False Advertising
Negative
Forbes
7 hours ago
Novo Nordisk Sues GLP-1 Rival Eli Lilly For Misleading Advertising
Ozempic drugmaker Novo Nordisk sued rival GLP-1 manufacturer Eli Lilly in federal court Tuesday, accusing the company of using “intentionally selected outdated studies” to curate allegedly misleading ad campaigns that exaggerate the efficacy of Lilly's products.
Novo Nordisk Sues GLP-1 Rival Eli Lilly For Misleading Advertising
Negative
Invezz
7 hours ago
Novo Nordisk sues Eli Lilly over weight-loss drug advertising claims
Novo Nordisk has filed a lawsuit against Eli Lilly (LLY) in a US federal court, accusing its rival of running false and misleading advertising campaigns for its blockbuster diabetes and weight-loss drugs. The lawsuit, filed Tuesday in the US District Court for the District of New Jersey, alleges that Eli Lilly and Lilly USA violated federal and state false advertising and unfair competition laws, including the Lanham Act.
Novo Nordisk sues Eli Lilly over weight-loss drug advertising claims
Negative
Market Watch
8 hours ago
Novo Nordisk sues Eli Lilly over ads comparing GLP-1 medications
The drugmaker says Lilly isn't including the most up-to-date clinical information about its drugs
Novo Nordisk sues Eli Lilly over ads comparing GLP-1 medications
Negative
WSJ
8 hours ago
Novo Nordisk filed a lawsuit against rival Eli Lilly accusing it of using outdated studies to promote its GLP-1 drugs
The maker of Ozempic and Wegovy says its competitor is misleading consumers by citing outdated weight-loss data in advertisements.
Novo Nordisk filed a lawsuit against rival Eli Lilly accusing it of using outdated studies to promote its GLP-1 drugs